Enanta Pharmaceuticals | ENTA - Pre Tax Profit


Enanta Pharmaceuticals reported $-22.71M in Pre-Tax Profit for its fiscal quarter ending in December of 2024.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Incyte USD 343.6M 46.34M Mar/2026
Insmed USD -162.1M 164.84M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
J&J USD 7.82B 2.86B Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Ligand Pharmaceuticals USD 56.78M 84.36M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 3.84B 802M Mar/2026
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Roche Holding CHF 4.79B 3.01B Jun/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026